Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

Table 3 Overall survival and breast cancer-specific survival for breast cancer cases by tumor hormone receptor status^a

	Inflammatory breast cancer		Locally advanced breast cancer		Metastatic breast cancer		Non-T4 breast cancer
	Positive^b	Not positive^b	Positive	Not positive	Positive	Not positive	Positive	Not positive
Overall mortality
Number of events	427	494	185	306	432	1,069	2,330	5,789
Number at risk	626	916	303	671	533	1,578	11,499	51,062
Unadjusted HR (95% CI)	1 (ref)	0.62 (0.55 to 0.71)	1 (ref)	0.56 (0.47 to 0.68)	1 (ref)	0.60 (0.53 to 0.67)	1 (ref)	0.52 (0.49 to 0.54)
Adjusted HR (95% CI)^c	1 (ref)	0.64 (0.56 to 0.73)	1 (ref)	0.49 (0.40 to 0.60)	1 (ref)	0.54 (0.48 to 0.61)	1 (ref)	0.61 (0.58 to 0.64)
Breast cancer-specific mortality
Number of events	338	318	138	129	340	739	1,239	1,313
Number at risk	626	916	303	671	533	1,578	11,499	51,062
Unadjusted HR (95% CI)	1 (ref)	0.52 (0.45 to 0.61)	1 (ref)	0.33 (0.26 to 0.42)	1 (ref)	0.54 (0.48 to 1.62)	1 (ref)	0.22 (0.21 to 0.24)
Adjusted HR (95% CI)^c	1 (ref)	0.55 (0.47 to 0.65)	1 (ref)	0.33 (0.25 to 0.43)	1 (ref)	0.51 (0.44 to 0.58)	1 (ref)	0.43 (0.39 to 0.47)

^aUnivariate and multivariate adjusted analysis of overall survival and breast cancer-specific survival. Data for cases with missing hormone receptor status suppressed from table. ^bData presented as number of cases: not positive, not hormone receptor-positive; positive, hormone receptor-positive; ref, reference. ^cIncludes adjustment for age (years), ethnicity, grade, socioeconomic status quintile, treatment with surgery, radiation therapy, and chemotherapy. HR, hazards ratio; CI, confidence interval.

ISSN: 1465-542X